Vertex Pharmaceuticals Inc
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.
Profit margin of 32.9% — that's well above average.
Current Price
$446.78
+0.64%GoodMoat Value
$284.70
36.3% overvaluedVertex Pharmaceuticals Inc (VRTX) Insider Trades
VRTX Insider Trading Activity
Track insider trading transactions for Vertex Pharmaceuticals Inc (VRTX). Monitor recent buys, sells, and option exercises by officers, directors, and 10% beneficial owners. Insider trading activity can signal management confidence or concern about a stock's future prospects.
Current stock price: $446.78. Market cap: $113.36B. This page displays the most recent insider transactions for VRTX, including the insider's name, title, transaction type (purchase, sale, or option exercise), number of shares, and total value. Filter transactions by type to focus on open-market purchases or sales.
Insider buying is often viewed as a bullish signal, as insiders are putting their own capital at risk. Conversely, large insider sales may warrant further investigation. Use GoodMoat's insider trading data alongside financial analysis, quality scores, and valuation tools for a comprehensive view of Vertex Pharmaceuticals Inc's investment outlook.